Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 3
2008 2
2009 2
2010 2
2011 5
2012 2
2013 1
2014 1
2017 1
2018 1
2019 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

19 results
Results by year
Filters applied: . Clear all
Page 1
Antibody conjugates and therapeutic strategies.
McCarron PA, Olwill SA, Marouf WM, Buick RJ, Walker B, Scott CJ. McCarron PA, et al. Among authors: olwill sa. Mol Interv. 2005 Dec;5(6):368-80. doi: 10.1124/mi.5.6.9. Mol Interv. 2005. PMID: 16394252 Review.
New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016.
Adusumilli PS, Cha E, Cornfeld M, Davis T, Diab A, Dubensky TW Jr, Evans E, Grogan JL, Irving BA, Leidner RS, Olwill SA, Soon-Shiong P, Triebel F, Tuck D, Bot A, Dansey RD, Drake CG, Freeman GJ, Ibrahim R, Patel S, Chen DS. Adusumilli PS, et al. Among authors: olwill sa. J Immunother Cancer. 2017 Jun 20;5:50. doi: 10.1186/s40425-017-0253-2. eCollection 2017. J Immunother Cancer. 2017. PMID: 28649381 Free PMC article. Review.
Tumor-Localized Costimulatory T-Cell Engagement by the 4-1BB/HER2 Bispecific Antibody-Anticalin Fusion PRS-343.
Hinner MJ, Aiba RSB, Jaquin TJ, Berger S, Dürr MC, Schlosser C, Allersdorfer A, Wiedenmann A, Matschiner G, Schüler J, Moebius U, Rothe C, Matis L, Olwill SA. Hinner MJ, et al. Among authors: olwill sa. Clin Cancer Res. 2019 Oct 1;25(19):5878-5889. doi: 10.1158/1078-0432.CCR-18-3654. Epub 2019 May 28. Clin Cancer Res. 2019. PMID: 31138587 Free article.
Sustained plasma hepcidin suppression and iron elevation by Anticalin-derived hepcidin antagonist in cynomolgus monkey.
Hohlbaum AM, Gille H, Trentmann S, Kolodziejczyk M, Rattenstetter B, Laarakkers CM, Katzmann G, Christian HJ, Andersen N, Allersdorfer A, Olwill SA, Meibohm B, Audoly LP, Swinkels DW, van Swelm RPL. Hohlbaum AM, et al. Among authors: olwill sa. Br J Pharmacol. 2018 Apr;175(7):1054-1065. doi: 10.1111/bph.14143. Epub 2018 Feb 23. Br J Pharmacol. 2018. PMID: 29329501 Free PMC article.
Antibody targeting of Cathepsin S induces antibody-dependent cellular cytotoxicity.
Kwok HF, Buick RJ, Kuehn D, Gormley JA, Doherty D, Jaquin TJ, McClurg A, Ward C, Byrne T, Jaworski J, Leung KL, Snoddy P, McAnally C, Burden RE, Gray B, Lowry J, Sermadiras I, Gruszka N, Courtenay-Luck N, Kissenpfennig A, Scott CJ, Johnston JA, Olwill SA. Kwok HF, et al. Among authors: olwill sa. Mol Cancer. 2011 Dec 14;10:147. doi: 10.1186/1476-4598-10-147. Mol Cancer. 2011. PMID: 22168338 Free PMC article.
Multiplex immunoassay for serological diagnosis of Mycobacterium bovis infection in cattle.
Whelan C, Shuralev E, O'Keeffe G, Hyland P, Kwok HF, Snoddy P, O'Brien A, Connolly M, Quinn P, Groll M, Watterson T, Call S, Kenny K, Duignan A, Hamilton MJ, Buddle BM, Johnston JA, Davis WC, Olwill SA, Clarke J. Whelan C, et al. Among authors: olwill sa. Clin Vaccine Immunol. 2008 Dec;15(12):1834-8. doi: 10.1128/CVI.00238-08. Epub 2008 Oct 15. Clin Vaccine Immunol. 2008. PMID: 18927068 Free PMC article.
A highly potent and specific MET therapeutic protein antagonist with both ligand-dependent and ligand-independent activity.
Olwill SA, Joffroy C, Gille H, Vigna E, Matschiner G, Allersdorfer A, Lunde BM, Jaworski J, Burrows JF, Chiriaco C, Christian HJ, Hülsmeyer M, Trentmann S, Jensen K, Hohlbaum AM, Audoly L. Olwill SA, et al. Mol Cancer Ther. 2013 Nov;12(11):2459-71. doi: 10.1158/1535-7163.MCT-13-0318. Epub 2013 Sep 3. Mol Cancer Ther. 2013. PMID: 24002935 Free article.
19 results